Arun Upadhyay
Known title: Chief Scientific OfficerCIK: 0001960039
Associated companies
Transaction History
| OCGN | ▼ Sell | Tax Withholding | 41,633 | $37K | 1/3/2025 | View on chart |
| OCGN | ▼ Sell | Tax Withholding | 842 | $985 | 9/16/2024 | View on chart |
| OCGN | ▼ Sell | Tax Withholding | 917 | $1K | 6/17/2024 | View on chart |
| OCGN | ▼ Sell | Tax Withholding | 41,633 | $27K | 1/3/2024 | View on chart |
| OCGN | ▼ Sell | Tax Withholding | 842 | $345 | 9/16/2023 | View on chart |
| OCGN | ▼ Sell | Tax Withholding | 917 | $468 | 6/16/2023 | View on chart |
| OCGN | ▼ Sell | Tax Withholding | 7,102 | $9K | 1/3/2023 | View on chart |
| OCGN | ▲ Buy | Grant | 315,924 | $0 | 1/3/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Ocugen Secures Bahamas Approval for Gene Therapy OCU400
Ocugen received provisional approval from the Bahamas regulator to supply its gene‑therapy OCU400 for retinitis pigmentosa. The company will provide the treatment through an expanded access program and aims to treat the first patient within 90 days. The approval also grants priority designation under the Bahamas Longevity and Regenerative Therapies Act. This development may broaden global access for Ocugen’s therapy.
Ocugen Secures Bahamas Approval for Gene Therapy OCU400. Ocugen received provisional approval from the Bahamas regulator to supply its gene‑therapy OCU400 for retinitis pigmentosa. The company will provide the treatment through an expanded access program and aims to treat the first patient within 90 days. The approval also grants priority designation under the Bahamas Longevity and Regenerative Therapies Act. This development may broaden global access for Ocugen’s therapy.